USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the venture investment activity in life sciences for the past year. In order to have a successful life sciences R&D program, biotech and pharma companies must develop game-changing therapeutics, companion diagnostics and personalized…
USA With an increasing number of NFL players relying on potentially dangerous prescription painkillers, does the league need to relax its attitude to medical cannabis? The US National Football League (NFL) is a juggernaut. Even with decreased television ratings in 2017, the league’s revenue was up. Each of the NFL’s…
USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) discusses the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES) and how it will improve access to medicines and restore healthy competition to the market. American taxpayers, along with millions of patients, will benefit…
USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the healthcare market for 2018. Following a decade high of VC invested in 2017, and on a record pace again in 2018, valuations continue to move higher across all stages within…
Innovation Buck Dossey, an expert in digital marketing and audience manager at Adobe, discusses consumer needs in healthcare and the importance of adopting a digital health strategy. Joining the digital transformation race today means that many companies will have to transform to become digitally agile. While the topic of digital transformation permeates…
Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices. The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…
Biotech Pfizer has teamed up with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company based in Boston that will focus on developing treatments for a number of central nervous system (CNS) disorders. It has almost been a year since Pfizer announced that they were to cease R&D in new neuroscience…
USA After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here she discusses the importance of community for tackling rare…
Cannabis The opioid epidemic has reached new heights of late, claiming an estimated 40,000 American lives every year. The highly addictive nature of opium-derived medicine is the cause of the rising number of overdoses in the US and Canada. There are companies out there that are working to manufacture a new…
Innovation Meghann Chilcott, Senior Vice President of OrderInsite, discusses the changing role of pharmacists and technicians. Patients are consumers, and they expect more from pharmacies than a collection of pill bottles. Local pharmacists have seen their roles continually change over recent years due to enhanced technology that allows them better…
Innovation Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMSS) for PharmaBoardroom. We must assertively bend the arc of technology towards our patients, clinicians, researchers, and caregivers, and re-humanise the health system. One of the many ways patients are de-humanized in a health…
Opioids Today the USA finds itself in the midst of an opioid crisis, claiming 40,000 American lives every year – a comparable death toll to the HIV epidemic at its peak. Aside from the devastating human cost, it imposes a staggering annual economic burden of $504 billion US dollars, around three…
See our Cookie Privacy Policy Here